

T Cell Receptor V β Gene Bias in Rheumatoid Arthritis

Robert N. Jenkins, Afzal Nikaein, Alice Zimmermann, Katheryn Meek, and Peter E. Lipsky

The Harold C. Simmons Arthritis Research Center and Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas 75235; and Department of Transplant Immunology, Baylor University Medical Center, Dallas, Texas 75246

Abstract

Polymerase chain reaction (PCR) technology was employed to examine peripheral blood and synovial T cells in patients with rheumatoid arthritis (RA) for biased utilization of T cell receptor (TCR) variable region (V) genes. Oligonucleotide primers specific for individual TCR V β gene families were used to amplify TCR gene products in a semiquantitative assay of their relative utilization in unselected T cell populations. Mean V β expression in 24 RA peripheral blood samples was very similar to that in a panel of 15 normal subjects, except for a slight decrease in V β 13.2 expression. V β utilization in 8 RA synovial tissue samples and 13 synovial fluid samples was compared to simultaneously obtained blood samples. Although heterogeneous patterns of skewed V β utilization were observed, several significant trends emerged. By a number of approaches to data analysis, a statistically significant increase in expression of V β 6 and V β 15 in synovial T cells was documented. In addition, increased synovial expression of V β 14 was found, but only in the synovial fluid samples. Reduced expression of V β 1, V β 4, V β 5.1, V β 10, V β 16, and V β 19 was also observed in synovial T cells. These results indicate that biased V β gene utilization in different peripheral compartments of RA patients can be observed in unselected T cell populations, and are consistent with the conclusion that populations of T cells expressing these V β gene products may be involved in the pathogenesis of the disease. (*J. Clin. Invest.* 1993. 92:2688–2701.) Key words: polymerase chain reaction • rheumatoid arthritis • synovial T cells • T cell receptor • T cell repertoire

Introduction

Rheumatoid arthritis (RA) is an idiopathic disease characterized by chronic inflammation of synovium, local destruction of cartilage and bone, and systemic illness. Several lines of evidence implicate T cells which respond to antigenic stimuli via their α/β T cell receptor (TCR)¹ in the disease process (1). The majority of RA patients express products of a set of alleles

Address reprint requests to Dr. Robert N. Jenkins, Division of Rheumatic Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-8884.

Received for publication 5 March 1993 and in revised form 20 May 1993.

1. Abbreviations used in this paper: C or V, constant or variable region (gene); DMARD, disease-modifying antirheumatic drug; NSAID, non-steroidal antiinflammatory drug; RF, rheumatoid factor; RT, reverse transcriptase.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.
0021-9738/93/12/2688/14 \$2.00

Volume 92, December 1993, 2688–2701

at the B1 locus of the HLA-DR region, HLA-DRB1*0401 (HLA-DR4, Dw4), *0404/*0408 (DR4, Dw14), *0405 (DR4, Dw15), *0101 (HLA-DR1), and *1402 (HLA-DRw14, Dw16), that are associated with increased risk for acquiring the disease (2–7). These class II MHC molecules share a sequence of amino acids in the third hypervariable region (residues 70–74) of the HLA-DR β 1 chain, indicating that this epitope may confer disease susceptibility (8). Because the major roles of class II molecules are to bind and present antigenic peptides to CD4⁺ T cells or to exert an influence on thymic selection of the CD4⁺ T cell repertoire, these findings are compatible with the conclusion that the introduction of an unidentified pathogenic antigen into the synovial membrane of an immunogenetically susceptible host triggers a CD4⁺ T cell-mediated autoimmune response resulting in the manifestations of RA.

A number of studies have established the ability of antigen or autoantigen plus MHC combinations to select for T cells expressing particular TCR genes (9). There is also evidence that the variable region (V) gene expression profile of peripheral T cells can be influenced by the MHC molecules encountered during thymic education (10–13). In addition, it has been postulated that superantigens, characterized in part by their ability to stimulate T cells utilizing particular V β genes, may play a role in the development of autoimmunity including RA (14, 15). Thus, there are several factors that could lead to the development of biased TCR expression in RA.

Initial studies sought evidence of biased TCR expression in RA by looking for the presence of oligoclonal T cells. Evidence of oligoclonality manifested by the presence of rearranged bands detected by Southern blotting was rarely found in T cells directly isolated from synovial fluid samples (16, 17). Moreover, T cell clones established in culture conditions designed to allow outgrowth of all cells rarely exhibited identical rearrangements (18, 19). However, some studies were able to detect oligoclonality of synovial T cells selected for the ability to grow in IL-2 alone (20, 21). Even when oligoclonality was claimed, however, there was no consensus on the specific dominant rearrangement in different patient samples (22, 23). Taken together, these studies indicate that there is minimal oligoclonality in the rheumatoid synovium, although selection for IL-2-responsive T cells may induce outgrowth of a limited number of clones. A major limitation of these analyses, however, is that examination of cells for identical rearrangement patterns might not detect the predominance of an antigen- or superantigen-reactive T cell population utilizing particular V α or V β gene families.

Several studies have examined RA synovial fluid or synovial tissue for restricted expression of TCR V α or V β . Some have interpreted their results to indicate that the number of V β , but not V α , gene families expressed in synovial T cells is limited (24), whereas others have reported that, at least in patients with early disease, a limited number of V α , but not V β , gene families are expressed (25). Although variable numbers of V α and V β products were also detected in other studies of synovial

fluid or synovial tissue samples (14, 26), two recent analyses of synovial fluid T cells detected all of the V β families in every patient (27, 28). Thus, no consensus concerning the potential biased expression of V β or V α in RA synovium has emerged from these studies, most of which examined small numbers of patients. Some studies included comparisons of V gene expression in rheumatoid peripheral blood and synovial T cells. Analyses of increased synovial T cell expression of individual V gene families have generally demonstrated heterogeneous patterns (27–30). However, Paliard et al. (14) reported that, in nine of nine RA patients, expression of V β 14 was greater in synovial fluid T cells than in the peripheral blood. An increase in V β 14 expression in synovial fluid T cells in comparison to peripheral blood was found in one other study (29), but not in two others (27, 28). Therefore, the question of whether there is biased representation or activation of T cells expressing particular V α or V β products in rheumatoid synovium remains unresolved.

The present report of 24 RA patients used semiquantitative PCR amplification of cDNA with V β -specific primers to test the possibility that T cells in the peripheral blood, synovial fluid, or synovial tissue exhibit biased V β gene utilization. Several approaches to data analysis indicate biased V β gene utilization by T cells in patients with RA. Although the differences are small, several statistically significant trends were noted, with either enrichment or depletion of particular V β genes noted in the synovium or the peripheral blood. These data indicate that biased V β gene family utilization in different peripheral compartments of rheumatoid patient can be observed in unselected T cell populations and are consistent with the conclusion that T cells expressing these particular TCR gene products may be involved in the pathogenesis of RA.

Methods

Subjects. 24 patients who fulfilled the 1987 American College of Rheumatology criteria (31) for RA were studied. Synovial tissue was obtained from 8 patients undergoing synovectomy or joint replacement surgery, and synovial fluid was obtained from 11 patients undergoing therapeutic arthrocentesis. Synovial fluid was obtained from two of these patients on two occasions for a total of 13 synovial fluid samples. Peripheral blood was obtained from each of these patients, and from 5 similar patients from whom analysis of synovial T cells was not successful. Peripheral blood and synovial tissue or synovial fluid samples were obtained from 4 control patients with other arthritides. The disease characteristics, age, sex, and medications used by these subjects at the time samples were obtained are presented in Table I. The presence or absence of circulating rheumatoid factors was determined by nephelometry, except for a few cases in which a latex fixation test was used. Peripheral blood samples from 15 subjects who did not have arthritis served as normal controls.

HLA typing. Peripheral blood lymphocytes were used for serologic HLA class II typing by the lymphocytotoxicity method (32). Oligonucleotide typing of HLA class II genes was then performed according to previously published methods (33, 34). DNA was extracted from lymphocytes as described (35), and amplified by PCR using previously described primers for DR β (33), DQ β (36), DP β (36), and DR4 subtyping. Previously described oligonucleotides were used for probing dot blots of the DR β (33), DP β (36), DQ β (34), and DR4 (36) PCR products.

Cell preparation for TCR analysis. PBMC and synovial fluid mononuclear cells were prepared from heparinized samples by density gradient centrifugation over ficoll diatrizoate gradients. These cells were either used directly for RNA preparation or further enriched for T cells

by rosetting with neuraminidase-treated sheep erythrocytes and/or passage over a nylon wool column. Lymphocytes were prepared as described (37) from those synovial tissue samples not used directly for RNA preparation. Briefly, tissue was minced with scissors and digested with 1 mg/ml collagenase for 1–2 h at 37°C, and then passed rapidly over a nylon wool column.

RNA and cDNA preparation. RNA was directly prepared from synovial tissue samples by homogenization in guanidine thiocyanate with a tissue homogenizer followed by ultracentrifugation through a CsCl gradient as described (38). Cell preparations were homogenized in guanidine thiocyanate by repeated passage through a small gauge needle. Total RNA was extracted from cell homogenates as previously described (39). 1–6 μ g of RNA was converted to cDNA by incubation with 8 U avian myeloblastosis virus reverse transcriptase (RT) and 20 μ g/ml oligo-dT primers in the presence of actinomycin D (50 μ g/ml) for 1 h at 42°C. The cDNA was heated to 95°C for 5 min and then diluted to a final volume equal to the greater of 25 μ l per 1 μ g of RNA, or 80 μ l.

TCR β -chain PCR. In preliminary experiments, each cDNA was examined, alongside a positive control, in constant region (C) amplifications to determine the relative amount of TCR-derived cDNA. C β amplifications were done with primers 5'C β : GTGTTTGAGCCA-TCAGAA-GCA and 3'C β : AAGCCACAGTCTGCTTACC. For the RNA samples from patients RA5 through RA24 (Table I) and from all of the control subjects a negative control cDNA, prepared from RNA without added RT, was tested with C β region primers to ensure there was no contaminating TCR DNA. Products were sampled after 20, 25, 30, and 35 cycles to determine the number of cycles through which the specific product accumulated exponentially (see Fig. 1 A). The subsequent semiquantitative assay utilized the 22 V β family-specific 5' primers designed by Choi et al. (40) and the reverse primer 3'C β : ACCCACCAGCTCAGCTCCA in separate simultaneous PCR reactions. The number of cycles used (usually 22–30) was designed to stop the reactions while all of the products were still accumulating exponentially, as determined in the preliminary experiment. These steps were taken to ensure that each PCR product was proportional to the amount of corresponding mRNA. In addition, when possible, all of the reagents were aliquoted from a master mix so that pipetting variability did not produce artifacts in the PCR. In each experiment a negative control, with no cDNA added, was run in parallel for all primer pairs. PCR amplification of cDNA samples from subjects RA-1, RA-2, CP-4, and one of the sets of synovial fluid and peripheral blood samples from RA-3 was performed in individual tubes in a reaction volume of 50 μ l. Amplification of samples from RA-7, NC-11, and one of two sets of synovial fluid mononuclear cell and PBMC samples from RA-11 was carried out in triplicate in tubes. PCR amplification of the remaining 60 cDNA samples was carried out in triplicate 20- μ l reactions using 96-well microtiter plates in a model PTC-100-96 thermal controller (MJ Research, Watertown, MA). Triplicate amplifications were performed to further the reproducibility of the assay. The standard error of the three replicate determinations was usually < 10% of the corresponding mean. The reaction mixture contained 0.2 mM dNTPs (20 nM each of dATP, dCTP, dGTP, and dTTP), 1.5 mM MgCl₂, 0.3 μ M oligonucleotide primers, and 20–40 U/ml Taq DNA polymerase (Promega Corp., Madison, WI). The temperatures used in the PCR were 94°C for denaturation, 50°C for annealing, and 72°C for polymerization. The duration of each step was 1 min.

Determination of V β gene family utilization. A sample of each PCR amplification was transferred to a nylon membrane (Zeta-Probe GT, Bio-Rad Laboratories, Richmond, CA) by alkaline transfer using a slot blot apparatus. Blots were incubated in hybridization fluid (38) containing 6 \times sodium chloride, sodium citrate (SSC), 10% Denhardt's reagent, 100 μ g/ml denatured, fragmented salmon sperm DNA, and 0.5% SDS for at least 1 h at 37°C. The specific β -chain products were then detected by incubation of the blots for 3–24 h at 37°C in hybridization fluid containing [γ -³²P]-labeled β probe: ATTCTCCCACAC-CCAAAAGG, derived from the C β region. The β probe oligonucleotide was end-labeled with T4 polynucleotide kinase using standard

Table 1. Subjects Studied

| Donor | Diagnosis | Age/ duration | Race/Sex | RF | Disease characteristics | Medications | DR | DQ | Samples |
|---------------------------|-----------|------------------|----------|----|---------------------------|--------------------------|------------------|------------|---------------|
| RA patients | | | | | | | | | |
| RA-1 | RA | 52/1 | B/F | + | nodular, erosive, class 3 | NSAID | 2, 6, w52 | w1 | blood |
| RA-2 | RA | 73/7 | W/F | + | erosive, class 3 | NSAID, Gold | 4, 11, w52, w53 | w7(3) | blood |
| RA-3 | RA | 56/2 | B/F | + | erosive, class 3 | NSAID | 3, 11, w52 | w4, w7(3) | SF, blood* |
| RA-4 | RA | 62/25 | B/F | + | erosive, class 3 | NSAID, D-Pen | 4, 8, w52, w53 | w7(3) | blood |
| RA-5 | RA | 62/17 | W/F | + | nodular, erosive, class 3 | NSAID, MTX | 1, 4, w53 | w1, w7 | tissue, blood |
| RA-6 | RA | 37/1 | B/F | + | class 2 | NSAID, HCQ | 4, 11, w52, w53 | w1, w3 | SF, blood |
| RA-7 | RA | 58/12 | B/M | + | nodular, erosive, class 3 | NSAID, Gold | 4, 13, w52, w53 | w1, w3 | SF, blood |
| RA-8 | RA | 26/4 | W/F | + | erosive, class 3 | NSAID, MTX | 3, 7, w52, w53 | w2 | tissue, blood |
| RA-9 | RA | 57/5 | As/F | - | erosive, class 3 | NSAID | 2, 12, w52 | w7, w1 | blood |
| RA-10 | RA | 61/19 | W/F | + | erosive, class 3 | MTX, Pred | 7, 8, w52, w53 | w2, w4 | tissue, blood |
| RA-11 | RA | 63/2 | B/F | + | erosive, class 3 | NSAID, PRED, MTX | 3, 13, w52 | w1, w2? | SF, blood* |
| RA-12 | RA | 26/1 | L/F | + | class 2 | NSAID | 4, 7, w53 | w2, w3 | SF, blood |
| RA-13 | RA | 59/2 | B/F | + | erosive, class 2 | NSAID, MTX | 2, 13, w52 | w1, w7(3) | SF, blood |
| RA-14 | RA | 47/4 | W/F | + | nodular, erosive, class 3 | NSAID, MTX, HCQ, Pred | 3, 4, w52, w53 | w2, w3 | blood |
| RA-15 | RA | 21/3 | LA/F | + | erosive, class 3 | NSAID | 2, 4, w53 | w7(3), w1 | SF, blood |
| RA-16 | RA | 24/1 | LA/F | - | erosive, class 3 | NSAID | 7, 10, w53 | w1, w2 | SF, blood |
| RA-17 | RA | 40/2 | LA/F | - | class 2 | NSAID | 1, 8, w52 | w1 | tissue, blood |
| RA-18 | RA | 57/10 | B/F | + | nodular, erosive, class 3 | NSAID, Gold | 4, 6, w52, w53 | w1, w3 | SF, blood |
| RA-19 | RA | 66/10 | B/F | + | erosive, class 3 | NSAID, Gold | 3, 11, w52, w53 | w4, w7(3) | SF, blood |
| RA-20 | RA | 70/3 | W/F | + | nodular, erosive, class 2 | NSAID, PRED, MTX | 3, 4, w52, w53 | w2, w3 | tissue, blood |
| RA-21 | RA | 57/3 | B/F | + | erosive, class 3 | NSAID | ND [‡] | | tissue, blood |
| RA-22 | overlap | 50/12 | W/F | + | erosive, class 3 | NSAID | 6, 7, w52, w53 | w1, w2 | tissue, blood |
| RA-23 | RA | 42/1 | W/F | - | nodular, class 2 | NSAID, HCQ | 3, 7, w52, w53 | w2 | tissue, blood |
| RA-24 | RA | 56/12 | W/F | + | nodular, erosive, class 2 | NSAID, CyA | 1, 4, w53 | w1, w3 | SF, blood |
| Arthritic controls | | | | | | | | | |
| CP-1 | OA | 44/6 | B/M | - | | NSAID | ND | | SF, blood |
| CP-2 | OA | 76/20 | W/M | | | NSAID | ND | | blood |
| CP-3 | JCA | 24/20 | W/M | - | erosive, class 2 | NSAID, MTX | ND | | tissue, blood |
| CP-4 | JCA | 27/23 | W/F | - | erosive, class 2 | Pred, NSAID | 11, w53 | w7(3) | SF, blood |
| Normal controls | | | | | | | | | |
| NC-1 | | 30 | B/F | | | | ND | | blood |
| NC-2 | | 31 | W/F | | | | 12, 13, w52 | w1, w7(3) | blood |
| NC-3 | | 41 | B/F | | | | 8, 10, w52 | w1, w7 | blood |
| NC-4 | | 53 | W/F | | | | 11, 10, w52 | w1, w7 | blood |
| NC-5 | | 36 | B/F | | | | 6?, 11, w52, w53 | w1, w3 | blood |
| NC-6 | | 29 | W/M | | | | 7, - | w1, w2 | blood |
| NC-7 | | 36 | W/M | | | | 7, 11, w52, w53 | w7, w9 | blood |
| NC-8 | | 37 | W/M | | | | 1, 4, w53 | w1, w3(w7) | blood |
| NC-9 | | 28 | W/M | | | | 4, w6, w52, w53 | w1, w3NT | blood |
| NC-10 | | 31 | W/F | | | | 7, 9, w52, w53 | w1, w2 | blood |
| NC-11 | | 30 | A/F | | | | 2, 4, w53 | w1, w3 | blood |
| NC-12 | | 33 | W/M | | | | 3, 4, w52, w53 | w2, w3 | blood |
| NC-13 | | 25 | W/F | | | | 8, -, w52 | w7(3) | blood |
| NC-14 | | 32 | B/M | | | | 3, 11, w52 | w2, w7(3) | blood |
| NC-15 | | 32 | W/M | | | | 3, 4, w52, w53 | w2, w3 | Blood |

Abbreviations used in this table: CyA, cyclosporine A; D-pen, D-penicillamine; HCQ, hydroxychloroquine; JCA, juvenile chronic arthritis; MTX, methotrexate; OA, osteoarthritis; Pred, prednisone.

* Synovial fluid and peripheral blood were obtained on two separate occasions from this patient.

‡ ND, not determined.

methodology (38). Blots were washed in a solution of 6× SSC and 0.5% SDS for 20 min at 50°C. Hybridized probe was quantified with the Radioanalytic Imaging System (AMBIS Systems Inc., San Diego). Background counts from areas of slot blots containing no detectable bands (water controls) were subtracted with the AMBIS software. Accordingly, the amount of hybridized probe is expected to be linearly related to the amount of PCR product. The specificity of these amplifications was confirmed by separating samples of products by electrophoresis on agarose gels, transferring to nylon membranes, and probing as described above. In preliminary experiments it was determined that all

Vβ products detectable on slot blots produced a single band of the correct size on the agarose gel blots.

The data are expressed as the mean of the triplicate samples (where applicable) of each Vβ amplification divided by the sum of the 22 Vβ amplifications. The proportion of each Vβ PCR product to the sum of all the Vβ products will, by design, reflect the proportion of total TCR mRNA that encodes a particular Vβ gene family. Control Cβ amplifications were performed in each experiment, but were not used to normalize the individual Vβ data because the sum of the individual Vβ/Cβ ratios was not consistent from one cDNA to another. Conse-

quently, differences in an individual $V\beta/C\beta$ ratio from one cDNA to another might reflect this inconsistency rather than true skewing. In contrast, when the data were normalized with the sum of the 22 $V\beta$ amplifications repeat experiments performed on the same cDNA produced nearly identical $V\beta$ expression profiles (see Results). This consistency allowed meaningful comparisons of different cDNAs.

The ability of this semiquantitative assay to detect selective expansion or activation of T cells bearing a particular $V\beta$ gene was demonstrated in preliminary experiments and in experiments published elsewhere. Peripheral T cells stimulated with monoclonal antibodies directed against specific $V\beta$ proteins in the presence of IL-2 produced at least a twofold increase in the amount of the appropriate $V\beta$ PCR product even though there was no detectable increase in the number of cells in culture (data not shown), demonstrating that increased amounts of mRNA resulting from activation of $V\beta$ -specific T cells could be detected. In addition, proliferation driven by $V\beta$ -specific superantigens resulted in a marked increase of the appropriate $V\beta$ PCR product (41). Finally, addition of small numbers of monoclonal T cell populations (5%) to T cells derived from the peripheral blood of a normal donor was easily detected (data not shown). These preliminary results confirmed that the semiquantitative PCR could detect changes in both the activation state and number of T cells expressing specific $V\beta$ gene products in a heterogeneous population.

Statistical analysis. $V\beta$ expression in the peripheral blood and synovium of RA patients and in the peripheral blood of control subjects was not normally distributed for every $V\beta$ gene family. Therefore, Wilcoxon's rank sum test was applied to comparisons of $V\beta$ expression in RA patients and control groups, and Wilcoxon's signed rank test was applied to comparisons of $V\beta$ expression in simultaneously obtained peripheral blood and synovial samples. Student's *t* test was applied to comparisons of $V\beta$ expression in peripheral blood and synovium in each experiment performed with triplicate PCR amplifications. Regression analysis was used to examine the overall similarity of $V\beta$ expression profiles in different experiments. The coefficient of determina-

tion (r^2) is reported, with $r^2 = 1.0$ indicating perfect correlation, and $r^2 = 0$ indicating no correlation.

Results

Patient population. Samples were obtained from 24 RA patients, 4 patients with other arthritides, and 15 normal donors. The clinical characteristics of these subjects are presented in Table I. A large majority of the RA patients had erosive synovitis and all of them were functional class II or III (42). Rheumatoid factor (RF) was detected in the serum of 20 RA patients. A majority (15/24) of the RA patients was taking a disease-modifying antirheumatic drug (DMARD) at the time the samples were obtained. Of the 23 patients on whom serologic HLA-typing was available, 12 expressed either HLA-DR1 or HLA-DR4 or both. 5 of the 15 normal subjects tested positive for either or both of these markers. Of the 8 HLA-DR4+ patients who were DNA typed, 7 expressed at least one of the susceptibility conferring alleles DRB1 *0401, *0404, or *0408. For clarity of presentation, serologic typing of HLA-A, B, and C, and DNA analysis of DP, DQ, and DR4 subtypes, are not shown.

RA peripheral blood. Fig. 1 illustrates the protocol used in these experiments for the analysis of $V\beta$ gene family expression in unselected T cell populations. The preliminary analysis of the peripheral blood cDNA of one subject indicated that TCR $C\beta$ product accumulated exponentially for 30 PCR cycles (Fig. 1A). Because the $C\beta$ primer pair amplifies all TCR β chain-derived cDNA, the individual $V\beta$ PCR products amplified from this cDNA would also accumulate exponentially for at least 30 cycles. The subsequent experiment utilized 28 PCR cycles for the triplicate amplification of this cDNA with the 22




Figure 1. Determination of T cell $V\beta$ gene family utilization in PBMC from patient RA-23. (A) PBMC cDNA was amplified with 5' $C\beta$ and 3' $C\beta$ for 35 PCR cycles. Samples were removed after 20, 25, 30, and 35 cycles, transferred to a slot blot, and hybridized with radiolabeled β probe. Net hybridized counts are depicted on the y-axis. (B and C) PCR amplifications of H₂O controls (B) and of PBMC cDNA (C) were performed for 28 cycles. Amplification of a control cDNA, prepared from RNA without the addition of RT, with $C\beta$ primers produced no detectable product after 28 cycles (data not shown). (B) Area of the slot blot containing samples of the H₂O controls for the PCR experiment depicted in C. (C) PBMC cDNA was amplified in triplicate using the 5' primers depicted on the left. Each slot represents a separate PCR reaction. The slot blot was hybridized with radiolabeled β probe, washed, and analyzed with the AMBIS system. The image is presented in log

mode for clarity. (D) Net hybridized counts (mean \pm SEM) were determined for each triplicate and are presented on the x-axis. The area of the slot blot depicted in B was used as the sample background.

V β gene family specific 5' primers. The hybridized slot blots of this experiment are shown in Fig. 1, B and C. Quantifying of the net hybridized counts, depicted in Fig. 1 D, indicated a low degree of well-to-well variability in the triplicate PCR amplifications. The normalized data from this experiment are depicted in Fig. 2. Each cDNA in this report was subjected to a similar analysis.

Circulating T cells from the blood of 24 RA patients with active disease were examined for biased TCR expression in comparison with TCR expression in the peripheral blood of 15 normal donors. Although two blood samples were available from 2 RA subjects, only one sample from each was used in this analysis. Restricted V β gene family utilization was not observed in RA patients nor in normal donors. For example, all of the 22 V β products were detected at levels exceeding 1% of the total in the blood of patient RA-23 (Fig. 1 C, and Fig. 2). At least 16 of the 22 V β products represented 1% or more of the total in every blood sample; the mean for all of the blood samples was 20 V β products > 1% (data not shown). Every V β family comprised 1% or more of the total in the peripheral blood of 90% or more of the subjects tested, except for V β 10 and V β 11 which were expressed to this level in 56% and 51%, respectively. The patterns of TCR expression were heterogeneous in both RA patients and controls. The data summarized in Table II indicate that the mean expression of each V β gene family was not markedly different in RA patients and normal donors. However, a statistically significant decrease in V β 13.2 expression in RA patients was observed. Comparison of the

peripheral blood T cell V β expression in the 20 RF+ to those of the normal donors produced results very similar to those obtained by analyzing all of the RA patients (data not shown).

To address the possibility that the RA patients who express HLA-DR1 or HLA-DR4 could represent a distinct subset, peripheral blood V β expression by these patients was compared to that of normal donors expressing either of these markers and the results are summarized in Table II. As in the previous comparisons V β 13.2 expression was lower in RA patients. V β 8 expression was also significantly lower in the patients than in the controls. In addition, RA patients in this group expressed significantly higher levels of V β 2 and V β 5.1 than did this normal donor group.

The potential effect of disease duration was explored by comparing peripheral blood V β expression in subjects having RA for 2 yr or less, and those having RA for more than 2 yr, to each other and to the normal subjects. There were no statistically significant differences between the group of 16 RA patients with longer disease duration and normal donors, nor between this group of patients and the group of 8 with shorter disease duration. However, V β 13.2 expression (3.0 \pm 0.5%) was lower in the patients with RA for 2 yr or less than in the normal donors (Table II) ($P < 0.004$), whereas V β 20 expression (4.1 \pm 0.5%) was higher in this group of RA patients ($P < 0.039$).

Similarly, the possibility that peripheral blood V β expression differed in patients taking nonsteroidal antiinflammatory drugs (NSAIDs) alone and patients taking DMARDs was ex-

Table II. V β Gene Family Utilization in Peripheral Blood of RA patients and Normal Donors

| V β gene family | All donors | | Donors expressing HLA-DR1 or HLA-DR4 | |
|-----------------------|------------------------|----------------------|--------------------------------------|--------------------------------|
| | Normal donors (n = 15) | RA patients (n = 24) | Normal donors (n = 5) | RA patients (n = 12) |
| V β 1 | 0.040 \pm 0.006 | 0.044 \pm 0.004 | 0.033 \pm 0.006 | 0.041 \pm 0.003 |
| V β 2 | 0.075 \pm 0.013 | 0.091 \pm 0.007 | 0.052 \pm 0.009 | 0.095 \pm 0.010 [†] |
| V β 3 | 0.053 \pm 0.010 | 0.060 \pm 0.009 | 0.085 \pm 0.018 | 0.080 \pm 0.015 |
| V β 4 | 0.075 \pm 0.010 | 0.066 \pm 0.005 | 0.066 \pm 0.007 | 0.071 \pm 0.009 |
| V β 5.1 | 0.043 \pm 0.006 | 0.047 \pm 0.004 | 0.029 \pm 0.004 | 0.053 \pm 0.006 [‡] |
| V β 5.2-3 | 0.034 \pm 0.006 | 0.035 \pm 0.004 | 0.027 \pm 0.008 | 0.038 \pm 0.004 |
| V β 6.1-3 | 0.102 \pm 0.007 | 0.106 \pm 0.008 | 0.093 \pm 0.006 | 0.089 \pm 0.005 |
| V β 7 | 0.096 \pm 0.007 | 0.093 \pm 0.007 | 0.099 \pm 0.010 | 0.088 \pm 0.012 |
| V β 8 | 0.086 \pm 0.007 | 0.078 \pm 0.006 | 0.101 \pm 0.010 | 0.070 \pm 0.007 [‡] |
| V β 9 | 0.044 \pm 0.005 | 0.049 \pm 0.004 | 0.054 \pm 0.006 | 0.049 \pm 0.006 |
| V β 10 | 0.014 \pm 0.003 | 0.013 \pm 0.001 | 0.013 \pm 0.004 | 0.011 \pm 0.002 |
| V β 11 | 0.012 \pm 0.002 | 0.013 \pm 0.002 | 0.015 \pm 0.004 | 0.013 \pm 0.004 |
| V β 12 | 0.029 \pm 0.005 | 0.028 \pm 0.003 | 0.035 \pm 0.007 | 0.030 \pm 0.005 |
| V β 13.1 | 0.057 \pm 0.006 | 0.051 \pm 0.004 | 0.053 \pm 0.004 | 0.048 \pm 0.007 |
| V β 13.2 | 0.053 \pm 0.004 | 0.038 \pm 0.004* | 0.053 \pm 0.005 | 0.029 \pm 0.004* |
| V β 14 | 0.034 \pm 0.003 | 0.027 \pm 0.003 | 0.033 \pm 0.004 | 0.025 \pm 0.003 |
| V β 15 | 0.023 \pm 0.003 | 0.027 \pm 0.003 | 0.021 \pm 0.004 | 0.025 \pm 0.004 |
| V β 16 | 0.020 \pm 0.002 | 0.018 \pm 0.002 | 0.020 \pm 0.002 | 0.018 \pm 0.002 |
| V β 17 | 0.043 \pm 0.006 | 0.032 \pm 0.004 | 0.042 \pm 0.009 | 0.037 \pm 0.005 |
| V β 18 | 0.020 \pm 0.003 | 0.023 \pm 0.002 | 0.026 \pm 0.005 | 0.026 \pm 0.004 |
| V β 19 | 0.021 \pm 0.003 | 0.027 \pm 0.006 | 0.020 \pm 0.005 | 0.032 \pm 0.011 |
| V β 20 | 0.028 \pm 0.004 | 0.035 \pm 0.005 | 0.030 \pm 0.004 | 0.033 \pm 0.005 |

Data represent mean \pm SE of the value V β / Σ V β determined for each case.

Wilcoxon's rank sum test, [†] $P \leq 0.023$, * $P \leq 0.01$, in comparison to corresponding group of normal donors.




Figure 2. Comparison of T cell V β gene family utilization in synovial tissue and PBMC from patient RA-23. RNA prepared directly from synovial tissue and was compared to that isolated from blood drawn at the time of surgery. Significantly different ($P < 0.05$) levels of V β gene family expression are noted (*).

amined by comparing these groups to each other and to the normal donors. There were no statistically significant differences in the peripheral blood expression of any V β families between the group of 15 patients taking DMARDs and the normal donors. In comparison to normal donors (Table II), the group of 9 patients taking NSAIDs alone exhibited reduced expression of V β 13.2 ($3.4 \pm 0.5\%$, $P < 0.009$) and V β 14 (2.2 ± 0.4 , $P < 0.026$). V β 1 expression was slightly higher in the patients taking NSAIDs alone than in the patients also taking DMARDs ($5.4 \pm 0.7\%$ vs. $3.8 \pm 0.3\%$, $P < 0.026$).

Taken together, these results suggest that the entire group of RA patients exhibited differences of a minor degree in V β gene expression in their peripheral blood in comparison to the entire control group of normal donors, but greater differences were observed if the comparison was limited to groups which expressed similar MHC class II alleles. Moreover, these analyses suggested that peripheral blood V β expression in the group of patients who had RA for 2 yr or less, and in those taking NSAIDs alone, differed from that in normal donors to a greater degree than did the group with longer duration disease or those taking DMARDs as well. Peripheral blood was also obtained from 4 arthritis patients with diagnoses other than RA and the V β expression in these samples was compared to that of the normal donors. There were no statistically significant differences in the mean expression of any V β gene family between these two control groups (data not shown).

Rheumatoid synovium. The possibility of skewing of V β expression in rheumatoid synovium compared to peripheral blood was examined in 21 samples from 19 patients. A number of statistical analyses were carried out to validate the biases observed (see below). Initially, we sought evidence of biased V β expression by comparison of the mean utilization of the group of synovial samples to that of the group of corresponding blood samples. In addition, each case was examined for a 50% difference between the synovial and blood T cells in the level of expression of each V β family. Finally, those cases in which triplicate amplifications were carried out were examined for statistically significant differences in V β expression regardless of the magnitude of the disparity. Comparison of group means has the potential advantage of revealing significant trends apparent in the entire group that could have been of modest magnitude in individual cases. On the other hand, if there was marked heterogeneity within the group, biologically meaningful differences in individual cases might be obscured. Tabulation of the number of individual comparisons in which a bias was either statistically significant or exceeded 50% was performed to address this possibility. In order to examine the possibility that biased V β utilization may be limited to certain subsets of RA patients, these analyses were performed on: (a) the entire set of samples; (b) those in which either synovial tissue or synovial fluid was analyzed; (c) samples from RF+ patients; (d) samples from subjects known to express HLA-DR1 or DR4; (e) samples from patients with RA for 2 yr or less, or for more than 2 yr; (f) samples from patients taking DMARDs; and (g) samples from patients taking NSAIDs alone.

The V β expression of T cells in synovial tissue at the time of joint replacement or synovectomy was determined in eight RA patients, six of whom were seropositive for RF. Histologic examination was performed on four of these synovial specimens and confirmed the presence of an active inflammatory infiltrate in each case. V β expression in simultaneously obtained peripheral blood T cells was used for comparison. An example of this type of experiment is shown in Fig. 2. Results of the comparison of the expression of each V β family in the eight synovial tissue samples to that of the corresponding peripheral blood samples are presented in Table III. There were statistically significant increases in V β 6.1-3 and V β 15 expression in synovial tissue as compared to peripheral blood, and a significant decrease in synovial tissue expression of V β 1 and V β 5.1. Moreover, mean expression of V β 6 and V β 15 in RA synovial tissue was significantly greater, and V β 5.1 expression significantly lower, than in normal donor peripheral blood ($P < 0.034$).

Synovial fluid samples obtained at the time of therapeutic arthrocentesis were also examined and compared to simultaneously obtained peripheral blood T cells in 13 RA cases (synovial fluid and blood were obtained from two patients on two occasions). 12 of the samples were obtained from RF+ patients. This analysis (Table III) revealed that V β 6.1-3 and V β 14 expression in the 13 synovial fluid T cell samples was significantly higher than that in the peripheral blood. On the other hand, synovial fluid expression of V β 4, V β 16, and V β 19 was significantly lower than in the peripheral blood samples. In addition, mean expression of V β 4, V β 16, and V β 19 in RA synovial fluid was significantly lower than in normal donor peripheral blood ($P < 0.014$).

As was the case with peripheral blood, restricted V β gene family expression was not observed in RA synovium. Levels of

Table III. Vβ Gene Family Utilization in RA Synovium and Simultaneously Obtained Peripheral Blood Samples

| Vβ gene family | Synovial tissue samples (n = 8) | | Synovial fluid samples (n = 13) | | All synovial samples (n = 21) | | HLA-DR-1/4 samples (n = 9) | |
|----------------|---------------------------------|--------------|---------------------------------|--------------------------|-------------------------------|--------------------------|----------------------------|--------------------------|
| | Blood | Tissue | Blood | Fluid | Blood | Synovium | Blood | Synovium |
| Vβ1 | 0.045±0.008 | 0.028±0.004* | 0.045±0.004 | 0.038±0.006 | 0.045±0.004 | 0.034±0.004* | 0.044±0.003 | 0.029±0.004* |
| Vβ2 | 0.084±0.012 | 0.114±0.022 | 0.097±0.009 | 0.107±0.010 | 0.092±0.007 | 0.109±0.010 | 0.096±0.012 | 0.100±0.016 |
| Vβ3 | 0.044±0.014 | 0.023±0.003 | 0.058±0.012 | 0.065±0.015 | 0.052±0.009 | 0.049±0.010 | 0.064±0.018 | 0.057±0.020 |
| Vβ4 | 0.065±0.005 | 0.041±0.009 | 0.075±0.008 | 0.040±0.005 [§] | 0.071±0.006 | 0.040±0.005 [§] | 0.080±0.010 | 0.042±0.005 [‡] |
| Vβ5.1 | 0.040±0.003 | 0.022±0.006* | 0.048±0.006 | 0.034±0.005 | 0.045±0.004 | 0.030±0.004 [‡] | 0.051±0.006 | 0.024±0.003 [‡] |
| Vβ5.2-3 | 0.031±0.004 | 0.032±0.007 | 0.034±0.007 | 0.030±0.004 | 0.033±0.005 | 0.031±0.004 | 0.034±0.004 | 0.028±0.004 |
| Vβ6.1-3 | 0.100±0.008 | 0.154±0.016* | 0.096±0.008 | 0.132±0.016 [‡] | 0.098±0.006 | 0.140±0.012 [§] | 0.089±0.007 | 0.138±0.022 [‡] |
| Vβ7 | 0.108±0.012 | 0.118±0.013 | 0.089±0.01 | 0.087±0.008 | 0.096±0.008 | 0.099±0.008 | 0.098±0.015 | 0.098±0.015 |
| Vβ8 | 0.094±0.011 | 0.074±0.011 | 0.082±0.008 | 0.094±0.015 | 0.086±0.007 | 0.086±0.010 | 0.076±0.009 | 0.091±0.020 |
| Vβ9 | 0.056±0.008 | 0.060±0.012 | 0.046±0.005 | 0.050±0.006 | 0.050±0.004 | 0.054±0.006 | 0.049±0.008 | 0.049±0.006 |
| Vβ10 | 0.012±0.002 | 0.007±0.002 | 0.015±0.002 | 0.012±0.002 | 0.014±0.001 | 0.010±0.001* | 0.011±0.002 | 0.007±0.002* |
| Vβ11 | 0.014±0.003 | 0.009±0.001 | 0.014±0.003 | 0.013±0.003 | 0.014±0.002 | 0.011±0.002 | 0.014±0.005 | 0.013±0.004 |
| Vβ12 | 0.026±0.003 | 0.020±0.004 | 0.029±0.004 | 0.029±0.007 | 0.028±0.003 | 0.025±0.004 | 0.026±0.006 | 0.024±0.005 |
| Vβ13.1 | 0.047±0.005 | 0.062±0.008 | 0.054±0.007 | 0.054±0.007 | 0.051±0.004 | 0.057±0.006 | 0.046±0.008 | 0.056±0.009 |
| Vβ13.2 | 0.047±0.007 | 0.037±0.006 | 0.036±0.005 | 0.031±0.004 | 0.040±0.004 | 0.033±0.004 | 0.036±0.007 | 0.034±0.007 |
| Vβ14 | 0.033±0.009 | 0.029±0.005 | 0.024±0.003 | 0.031±0.004 [‡] | 0.028±0.004 | 0.030±0.003* | 0.022±0.004 | 0.028±0.006 [‡] |
| Vβ15 | 0.018±0.002 | 0.037±0.005* | 0.033±0.005 | 0.037±0.004 | 0.027±0.004 | 0.037±0.003* | 0.024±0.005 | 0.040±0.003* |
| Vβ16 | 0.019±0.004 | 0.011±0.002 | 0.016±0.002 | 0.012±0.001* | 0.017±0.002 | 0.012±0.001 [‡] | 0.017±0.003 | 0.012±0.002 |
| Vβ17 | 0.037±0.007 | 0.030±0.005 | 0.030±0.004 | 0.033±0.007 | 0.033±0.004 | 0.032±0.005 | 0.038±0.007 | 0.039±0.009 |
| Vβ18 | 0.022±0.002 | 0.026±0.005 | 0.020±0.002 | 0.021±0.002 | 0.021±0.001 | 0.023±0.002 | 0.022±0.002 | 0.025±0.005 |
| Vβ19 | 0.023±0.004 | 0.026±0.007 | 0.024±0.004 | 0.011±0.002* | 0.024±0.003 | 0.017±0.003* | 0.026±0.006 | 0.018±0.007 |
| Vβ20 | 0.038±0.007 | 0.040±0.007 | 0.035±0.005 | 0.041±0.009 | 0.036±0.004 | 0.041±0.006 | 0.037±0.006 | 0.050±0.012 |

Data represent mean±SE of the value $V\beta/\Sigma V\beta$ determined for each case.

Wilcoxon's signed rank test, * $P < 0.05$, † $P \leq 0.01$, or § $P \leq 0.001$ in comparison to corresponding blood samples.

expression of at least 17 of the 22 Vβ products were > 1% in every synovial sample; the mean for the group was 20 Vβ products representing 1% or more of the total. Every Vβ family represented at least 1% of the total in the synovium of 90% or more of the RA patients, except Vβ10, Vβ11, Vβ12, Vβ16, and Vβ19 which were expressed at this level in 38%, 43%, 81%, 67%, and 53%, respectively. A comparison of the Vβ gene expression in all of the 21 synovial samples and the corresponding blood samples is presented in Table III. Vβ6.1-3 and Vβ15 were significantly overexpressed in rheumatoid synovium when all 21 samples were considered together ($P < 0.0005$ and $P < 0.05$, respectively). Although synovial T cell expression of Vβ14 expression was statistically significantly increased ($P < 0.02$), the difference in the means of the synovial and peripheral blood samples was extremely small (3.0% vs. 2.8%). The synovial T cell expression of Vβ1, Vβ4, Vβ5.1, Vβ10, Vβ16, and Vβ19 was significantly lower than expression in the corresponding RA peripheral blood samples ($P < 0.05$). In comparison to the peripheral blood of normal donors, the mean expression of Vβ6.1-3 and Vβ15 in the synovial samples was significantly greater ($P < 0.015$ and $P < 0.003$, respectively), and the mean expression of Vβ4 and Vβ16 was significantly lower ($P \leq 0.001$).

Similar results were obtained when the comparison was limited to the 18 RF+ cases (data not shown). If the analysis was limited to the nine cases where the samples were obtained from donors known to be HLA-DR1 or DR4+, increased synovial T cell Vβ6.1-3, Vβ14, and Vβ15 expression, and decreased synovial T cell Vβ1, Vβ4, Vβ5.1, and Vβ10 expression were again

noted (Table III). Moreover, in the synovium of this group of patients the mean Vβ15 expression was significantly higher ($P < 0.01$), and the mean Vβ4 and Vβ10 expression was significantly lower ($P < 0.014$), than that in the peripheral blood of normal donors known to express these HLA antigens.

Individual analysis of rheumatoid synovium and peripheral blood in the (a) 9 samples from patients with RA for 2 yr or less; (b) 12 samples from patients with disease for more than 2 yr; (c) 8 samples from patients taking NSAIDs alone; and (d) 13 samples from patients also taking DMARDs, each revealed biased expression of Vβ gene families very similar to that seen in the entire group of RA patients. Restricted expression of Vβ gene families was not observed in any of these groups of synovial T cell samples.

Bias in individual cases. It was evident that all individual comparisons of synovial and peripheral blood T cells did not exhibit the same pattern of biased V gene expression. To explore the possibility that biased utilization of some Vβ families by synovial T cells occurs more frequently than anticipated from the data in Table III, we examined all individual comparisons of synovium and blood for differences in expression of 50% or more, reasoning that such a difference is of sufficient magnitude to be of potential biologic importance. In the example shown in Fig. 2, synovial tissue expression of Vβ5.2-3, Vβ6.1-3, Vβ15, and Vβ19 was at least 50% greater than that of peripheral blood in this patient (RA-23). On the other hand, Vβ2, Vβ5.1, Vβ9, Vβ10, Vβ11, Vβ12, and Vβ16 expression was at least 50% greater in peripheral blood.

The number of cases in which expression of a particular Vβ

gene family differed by 50% or more in synovial tissue and peripheral blood is shown in Table IV. There are at least two examples of biased expression of every V β gene family. Increased synovial tissue expression of V β 15 and V β 6.1-3 was frequently seen, whereas V β 4, V β 5.1, V β 10, V β 12, V β 13.2, and V β 16 expression was frequently greater in the peripheral blood. Biased expression of V β 15 and V β 5.1 in the synovial tissue was found in all three of the donors known to express DR1 or DR4 or both.

Synovial fluid and peripheral blood samples were obtained on two occasions 9 mo apart from subject RA-11. These two comparisons of synovial fluid and peripheral blood are depicted in Fig. 3. At both time points it is clear that T cell V β expression is not identical in the synovial fluid and peripheral blood. Regression analysis was used to determine the degree of overall similarity of V β expression. The coefficient of determination (r^2) for peripheral blood and synovial T cell V β expression was 0.78 at the first time point and 0.84 at the second time point. This degree of similarity was relatively high in comparison to that observed in similar experiments; the mean r^2 for the 21 comparisons was 0.57 with 95% confidence intervals of 0.47–0.67. It is also evident from Fig. 3 that peripheral blood (and synovial fluid) T cell V β expression was not identical at both time points. Between time points in RA-11 the degree of similarity (r^2) for peripheral blood V β expression was 0.66, and for synovial fluid V β expression $r^2 = 0.70$. The variability of V β expression in the peripheral blood of RA-11 with time

was considerably less than that seen between this patient and the other RA patients where the mean $r^2 = 0.45$ (95% confidence interval of 0.38–0.52). In control experiments, the r^2 for repeat analysis of the same cDNA was 0.93 for the first RA-11 PBMC cDNA, and 0.91 for the second RA-11 PBMC cDNA. These results indicate that differences observed in comparisons of different cDNAs are unlikely to be artifactual.

Expression of 10 V β families differed by 50% or more in the first comparison of peripheral blood and synovial fluid T cells in RA-11, whereas 7 V β families differed to this degree in the second comparison (Fig. 3). Decreased synovial T cell expression of V β 4 and V β 19 was seen on both occasions, consistent with the overall similarity of both peripheral blood and synovial fluid V β expression at the two timepoints. Samples were also obtained from subject RA-3 on two occasions 3 mo apart (data not shown). The coefficient of determination for synovial fluid and peripheral blood expression was 0.76 at the first time point and 0.63 at the second time point. The variability of peripheral blood V β expression in this patient with time ($r^2 = 0.77$) was less than that seen between individuals (see above). Synovial fluid T cell V β expression exhibited a similar degree of variability with time ($r^2 = 0.68$). A 50% increase in synovial fluid expression of V β 7 and a 50% decrease in synovial fluid expression of V β 12 were observed on both occasions. A 50% bias was observed in the expression of four other V β gene families in only the first comparison, and six others in only the second comparison.

A summary of the 13 synovial fluid analyses is presented in Table IV. Heterogeneous skewing continued to be noted as there are at least two examples of biased expression for each V β gene family. Similar to the synovial tissue comparisons, increased synovial fluid expression of V β 15 and greater peripheral blood expression of V β 4, V β 5.1, V β 10, and V β 16 was frequently observed. In addition, there were several cases where synovial fluid expression of V β 1 and V β 19 was substantially less than that in the peripheral blood. There were only two cases in whom peripheral blood expression of V β 14 was 50% less than in the synovial fluid. Only one of the six RF+, HLA-DR1 or DR4 patients exhibited a 50% or greater decrease in peripheral blood expression of V β 14 in comparison to synovial fluid. Nevertheless, peripheral blood expression of V β 14 was modestly but significantly lower than that of synovial fluid in this group of six patients (2.5% vs. 3.4%, $P = 0.031$), as it was for the entire group of synovial fluid samples (Table III).

Taking the synovial tissue and synovial fluid samples together synovial and peripheral blood TCR V β expression was compared in 21 cases, 18 of which were from seropositive patients. Increased expression of V β 15, V β 6.1-3, V β 2, V β 12, and V β 13.1 was observed most frequently in synovial T cells, whereas increased expression of V β 4, V β 5.1, V β 10, V β 19, V β 16 and V β 1 was seen more frequently in peripheral blood (Table IV). When the samples were analyzed for larger differences between synovial and peripheral blood expression of individual V β gene families, biases continued to be noted. Thus, when twofold or greater differences were required, 9 of 18 RF+ patients exhibited increases in peripheral blood expression of V β 4 (no cases of opposite bias), whereas 8 RF+ patients manifested greater expression of V β 15 in synovial T cells (one case of opposite bias).

A comparison of synovial and peripheral blood T cell utilization of V β families was performed in eight seropositive RA patients who expressed HLA-DR1 or HLA-DR4 (Table IV).

Table IV. Skewed V β Gene Family Expression in RA Synovial Tissue and Fluid

| V β gene family | Synovial tissue cases (n = 8) | | Synovial fluid cases (n = 13) | | All RF+ HLA-DR-1/4+ comparisons (n = 8) | |
|-----------------------|-------------------------------|--------|-------------------------------|-------|---|----------|
| | Blood | Tissue | Blood | Fluid | Blood | Synovium |
| V β 1 | 2* | 0 | 6 | 2 | 5 | 0 |
| V β 2 | 1 | 3 | 0 | 2 | 1 | 2 |
| V β 3 | 4 | 1 | 2 | 2 | 3 | 2 |
| V β 4 | 5 | 1 | 9 | 0 | 5 | 0 |
| V β 5.1 | 6 | 1 | 7 | 1 | 6 | 0 |
| V β 5.2-3 | 2 | 2 | 4 | 2 | 1 | 1 |
| V β 6.1-3 | 0 | 4 | 0 | 2 | 0 | 4 |
| V β 7 | 1 | 2 | 2 | 2 | 1 | 2 |
| V β 8 | 3 | 1 | 1 | 2 | 0 | 2 |
| V β 9 | 2 | 1 | 1 | 3 | 0 | 1 |
| V β 10 | 5 | 1 | 7 | 2 | 4 | 0 |
| V β 11 | 3 | 0 | 5 | 3 | 3 | 0 |
| V β 12 | 4 | 1 | 4 | 4 | 2 | 2 |
| V β 13.1 | 0 | 3 | 2 | 2 | 1 | 2 |
| V β 13.2 | 4 | 0 | 3 | 1 | 1 | 1 |
| V β 14 | 1 | 0 | 0 | 2 | 0 | 2 |
| V β 15 | 0 | 6 | 3 | 6 | 0 | 3 |
| V β 16 | 4 | 0 | 5 | 0 | 2 | 0 |
| V β 17 | 2 | 1 | 4 | 3 | 3 | 1 |
| V β 18 | 1 | 3 | 3 | 1 | 0 | 0 |
| V β 19 | 3 | 2 | 8 | 1 | 3 | 1 |
| V β 20 | 2 | 1 | 1 | 2 | 0 | 1 |

* Number of cases in which expression was 50% greater in indicated compartment.




Figure 3. Comparison of T cell Vβ gene family utilization in synovial fluid mononuclear cell and PBMC from patient RA-11 on two occasions. In both experiments significantly different ($P < 0.05$) levels of Vβ gene family expression in SFMC and PBMC are noted (*).

Synovial T cell expression of V β 15 was at least 50% greater than peripheral blood in five of these patients, whereas increased peripheral blood expression of V β 1, V β 4, V β 5.1, V β 10, and V β 16 was seen in five, six, eight, six, and four cases, respectively.

In total, 19 comparisons of synovial and peripheral blood T cells were done using triplicate amplifications of cDNA with each primer pair. Statistical analysis could therefore be directly applied to these comparisons. Examination of the data in this way has the advantage of detecting biased V β gene expression that may be statistically significant but not of sufficient magnitude to meet the 50% cutoff used in the analyses presented above. For example, in the comparison shown in Fig. 2, synovial tissue T cell and peripheral blood T cell expression of V β 2, V β 5.1, V β 6.1-3, V β 12, V β 13.1, and V β 16 were significantly different ($P < 0.05$). The difference in V β 2 expression, however, was $< 50\%$. Similarly, in both of the experiments shown in Fig. 3 there were three examples of significant bias in which the magnitude of the difference was $< 50\%$. Table V presents the number of cases where expression of individual V β families was significantly increased in one compartment or the other. V β 2, V β 6.1-3, and V β 15 were the three families most frequently increased in synovial T cells, whereas there was a large number of cases of increased peripheral blood expression of V β 1, V β 4, V β 5.1, V β 10, and V β 19. Similar trends were seen in the group of 17 RF+ cases (data not shown), and the eight comparisons from RF+, HLA-DR1/4+ cases (Table V).

Table V. Statistically Significantly Biased V β Gene Family Expression in synovium vs. Peripheral Blood of RA Patients

| V β gene family | All comparisons (n = 19) | | All RF+ HLA-DR-1/4+ comparisons (n = 8) | |
|-----------------------|--------------------------|----------|---|----------|
| | Blood | Synovium | Blood | Synovium |
| V β 1 | 7* | 2 | 5 | 0 |
| V β 2 | 3 | 7 | 1 | 2 |
| V β 3 | 5 | 3 | 3 | 2 |
| V β 4 | 12 | 1 | 5 | 0 |
| V β 5.1 | 11 | 1 | 6 | 0 |
| V β 5.2-3 | 4 | 3 | 1 | 1 |
| V β 6.1-3 | 0 | 10 | 0 | 4 |
| V β 7 | 2 | 3 | 1 | 2 |
| V β 8 | 1 | 3 | 0 | 2 |
| V β 9 | 1 | 2 | 0 | 1 |
| V β 10 | 7 | 1 | 4 | 0 |
| V β 11 | 5 | 2 | 3 | 0 |
| V β 12 | 5 | 4 | 2 | 2 |
| V β 13.1 | 3 | 3 | 1 | 2 |
| V β 13.2 | 4 | 3 | 1 | 1 |
| V β 14 | 1 | 4 | 0 | 2 |
| V β 15 | 1 | 7 | 0 | 3 |
| V β 16 | 5 | 0 | 2 | 0 |
| V β 17 | 6 | 1 | 3 | 1 |
| V β 18 | 2 | 1 | 0 | 0 |
| V β 19 | 9 | 1 | 3 | 1 |
| V β 20 | 3 | 1 | 0 | 1 |

* Number of comparisons done with triplicate PCR amplifications in which expression was significantly greater in the indicated compartment ($P < 0.05$).

Of note, V β 6.1-3 was significantly overexpressed in 10 of 19 synovia (Table V), although this overexpression was $> 50\%$ in only 6 of 21 cases (Table IV). Similarly, there were only 2 of 13 cases where V β 14 expression was 50% less in peripheral blood than synovial fluid (Table IV), but of the 12 synovial fluid comparisons done in triplicate, 4 exhibited a statistically significant decrease in peripheral blood V β 14 expression (data not shown).

Discussion

The TCR repertoire of peripheral T cells is determined in part by the genetic elements which encode the TCR, by self-MHC antigen-directed positive and negative selection during thymic education, and presumably by the antigens or superantigens the individual has encountered. As RA is a chronic inflammatory disease with a genetic susceptibility linked to MHC class II genes, any or all of these determinants could produce a bias in the peripheral blood or synovial TCR repertoire. The present study provides the strongest evidence to date that biased V β gene utilization can be observed in unselected T cell populations from RA patients.

There was substantial subject-to-subject variability in peripheral blood V β gene expression both in normal donors and RA patients. Nevertheless, the mean expression of each V β gene family was not markedly different in RA patients, normal donors, or a small group of subjects with other arthritides. The mean expression of V β 13.2 was slightly lower in RA patients, however. Small differences in the expression of other V β gene families were also observed in both the subset of patients with RA for 2 yr or less and in the subset of patients taking NSAIDs alone. However, a longitudinal study of a larger number of patients would be needed to determine whether TCR bias in peripheral blood T cells is blunted by passage of time or treatment with DMARDs.

It is possible that the subtle bias in the V gene expression of peripheral T cells in RA results from encounters with superantigens, chronic stimulation by antigen, or from other factors known to influence V gene expression, such as differences in the MHC antigens expressed by the normal donors and the RA patients (11). To address the possibility that expression of specific HLA molecules may influence V β gene utilization we compared peripheral blood V β expression by RA patients who expressed the disease susceptibility conferring MHC class II molecules HLA-DR1, or HLA-DR4, to that of normal donors expressing either of these markers. This analysis revealed several significant differences between these groups. V β 13.2 and V β 8 expression was lower in the patients than in the controls, whereas V β 2 and V β 5.1 expression was higher. The observation that a greater degree of bias was evident in a comparison in which the two groups shared some MHC alleles suggests that events related to the disease process itself, such as antigen or superantigen stimulation, alter the expression of TCR V β products in the peripheral blood of RA patients.

Paliard et al. (14) observed that the expression of V β 14 in the peripheral blood of six of nine RA patients was undetectable or substantially diminished in comparison to peripheral blood of normal donors and arthritic controls. In the current study, the V β 14 PCR product was detectable in every RA patient and normal donor examined, representing 0.9% or more of the total. The mean expression in RA patients was lower than that in the control group (2.7% vs 3.4%), but the differ-

ence did not achieve statistical significance ($P = 0.07$). In the current group of RA patients known to express HLA-DR1 or DR4 (as did all of those studied by Paliard et al.) the mean peripheral blood expression of V β 14 was lower than that of the control donors who expressed these HLA antigens (Table III), but again the difference was not statistically significant ($P = 0.16$). Differences in the study populations may explain the somewhat disparate results obtained in these two studies. In addition, there were a number of methodological differences that might have influenced the results, including stimulation of the cells prior to RNA preparation in the aforementioned study as well as major differences in the PCR technique, means of normalization of the data, and data analysis. In preliminary experiments we have attempted to determine the impact of these variables on the data generated in each study, but have been unable to document that these methodological differences explain the disparate results. Thus, for example, we found that inclusion of an additional pair of oligonucleotides (such as C α primers) to provide an internal amplification control did not enhance the reproducibility of the V β amplifications. In addition, although we found that expression of a number of the V β families was significantly altered by stimulation of the cells with anti-CD3 antibodies and IL-2 before analysis, this did not decrease expression of V β 14 by blood T cells. Since most of the data was generated from triplicate PCR amplifications and the standard error of the mean was quite small, the current data persuasively argue that V β 14 is not substantially decreased in the blood of patients with RA. One other study of 3 RA patients and 2 normal donors came to a similar conclusion (27).

A number of previous studies have analyzed TCR V gene expression in RA using a variety of techniques, but did not produce a clear picture of the degree of restricted V gene expression in RA synovium or peripheral blood (Table VI). Studies examining RA peripheral blood and synovium for biased V gene expression have also not produced consistent results, perhaps because many of these examined only small numbers of patients. Two studies described greater synovial fluid expres-

sion of V β 14 (14, 29). In the current study V β 14 expression in synovial fluid was significantly greater than in the simultaneously obtained peripheral blood samples. This bias is consistent with the results of Paliard et al. (14). However, the magnitude of the difference was much less marked in the current study than in the prior study and was not observed in synovial tissue. It is noteworthy that V β 14 expression has been observed to be enriched in CD8+ T cells (43–45) which are usually increased in RA synovial fluid (46–48). Thus, it is possible that differences in V β 14 expression are at least partially related to alterations in the proportion of CD8+ cells found in peripheral blood and synovial fluid.

Immune responses to local introduction of an antigen result in infiltration by antigen-specific T cells and by large numbers of nonspecific T cells. Thus, one can assume that T cells responding to pathogenic peptides in rheumatoid synovium represent a small minority of infiltrating T cells. The large proportion of nonspecific T cells may produce variability in the V β expression profile of T cell populations with time as was noted in the samples obtained from the same patient at two points in time. These considerations may also partly explain the difference between the present study and those of others. Examination of a large number of patients with a semiquantitative approach comparing synovial and peripheral blood T cell V β expression in this study allowed the identification of biased TCR expression despite the presence of nonspecific T cells expressing other TCR V β gene products. Many of the previous reports studied an insufficient number of patients for consistent biases to emerge, or did not perform comparisons to peripheral blood rendering conclusions regarding TCR bias somewhat speculative. Moreover, the current study was designed to provide an accurate determination of V β expression by T cells as they are found in situ within the synovium or peripheral blood of RA patients. Therefore, stimulation of the cells prior to analysis, as was done in other studies, was avoided. Moreover, since there is no conclusive evidence that one or another of the specific T cell subsets present in the synovium is responsible for disease pathogenesis, no effort was made to isolate indi-

Table VI. Summary of Studies of V Gene Bias in RA

| Reference | n | Source of material | Synovial T cell expression | |
|-----------|----|--------------------|---|---|
| | | | Restricted | Biased* |
| 24 | 3 | SF and PB | V β 7 in 2 V α : no | |
| 14 | 9 | SF and PB | V β : no | V β 14 in 9 |
| 29 | 5 | SF and PB | V β : no | V β 14 in 3, V β 18 in 2 |
| 58 | 5 | IL-2R+ST T cells | V β 3 in 3, V β 9 in 3, V β 14 in 4, V β 17 in 4 | |
| 30 | 2 | SF | V α : no | V α 14, V α 15, V α FR1 |
| 25 | 9 | tissue | V β : no V α : heterogeneous number detected | |
| 26 | 10 | tissue | V β : heterogeneous number detected V α : heterogeneous number detected | |
| 27 | 3 | SF and PB | V β : no | V β 2 in 2 |
| 28 | 8 | SF and PB | V α : no V β : no | V α 10 in 3, V α 15 in 3, V α 18 in 3 V β 4 in 3, V β 5 in 3, V β 13 in 3 |

n, number of patients studied. Abbreviations used in this table: IL-2R, IL-2 receptor; PB, peripheral blood; SF, synovial fluid; ST, synovial tissue.
* Observations from two or more patients of increased synovial expression.

vidual subpopulations before analysis. Finally, the PCR approach we used to analyze $V\beta$ gene expression is sensitive to changes in the activation status of T cells as well as their number because recently activated T cells containing increased amounts of RNA result in an increased PCR product from the appropriate $V\beta/C\beta$ primer pair. These considerations support the conclusion that the biases reported in the current study which have not been reported in previous studies, and are rather small in magnitude, may reflect disease related differences in TCR $V\beta$ gene expression in blood versus synovium.

In the current report, the possibility of skewing of $V\beta$ expression in rheumatoid synovium compared to peripheral blood was examined in 21 samples from 19 patients. Whereas we found skewed expression of each $V\beta$ family in at least two comparisons, the current experimental results provide evidence for consistently increased expression of $V\beta 6$ and $V\beta 15$ in rheumatoid synovium. Expression of $V\beta 6.1-3$ in the 8 synovial tissue samples, in the 13 synovial fluid samples, and in the group including all 21 synovial samples was significantly higher than in the corresponding peripheral blood samples (Table III). Furthermore, in 10 of 19 comparisons done with triplicate amplifications synovial $V\beta 6.1-3$ expression was significantly higher than in peripheral blood (Table V), although the magnitude of increased expression was sometimes less than 50%. The expression of $V\beta 15$ in the synovial tissue samples, in the group of 21 synovial samples, and in the group of synovial samples from HLA-DR1/DR4+ patients was significantly greater than that in the simultaneously obtained peripheral blood samples (Table III). The bias toward synovial T cell expression of $V\beta 15$ was also apparent in synovial fluid samples in which 6 of 13 cases exhibited at least a 50% greater expression of $V\beta 15$ (Table IV). Thus, increased $V\beta 6.1-3$ and increased $V\beta 15$ expression in rheumatoid synovium were established by a number of analytic methods.

Evidence of biased $V\beta$ expression in rheumatoid synovium was also revealed by decreased expression of certain $V\beta$ families. $V\beta 1$, $V\beta 4$, $V\beta 5.1$, $V\beta 10$, $V\beta 16$, and $V\beta 19$ expression by synovial T cells was significantly lower than in the corresponding blood samples. It has been reported that $V\beta 5.1$ expression was skewed toward the CD4+ subset (43, 45, 49). This subset bias may contribute to the relative decrease in $V\beta 5.1$ expression in synovial fluid, but is probably less of a factor in synovial tissue where the relative proportion of CD4 and CD8 single positive cells is usually the same as in peripheral blood (37, 50). Evidence of similar bias in the expression of $V\beta 1$, $V\beta 4$, $V\beta 10$, $V\beta 16$, or $V\beta 19$ by CD4+ vs. CD8+ cells has not been reported and therefore alterations in expression of these are likely unrelated to biases of subset distribution in various compartments.

The analyses we performed did not suggest that the presence of RF, the expression of HLA-DR1 or DR4, the duration of disease, or the medications used had a substantial impact on the likelihood of detecting biased $V\beta$ expression in rheumatoid synovial T cells. Thus, the subset of synovial samples from seropositive patients, from patients known to express HLA-DR1 or DR4, from patients with RA for 2 yr or less, from patients with RA for more than 2 yr, from those medicated with NSAIDs alone, and from those also being treated with DMARDs all exhibited similarly biased TCR $V\beta$ expression in comparison to the corresponding peripheral blood samples. For example, all of the biases present in the HLA-DR1/4+ synovia were also present in the analysis of all 21 synovial

samples (Tables III and IV). However, greater numbers of seronegative RA patients, and longitudinal study of several patients, would be required to determine definitively the impact of RF, disease duration, or medications on $V\beta$ expression by synovial T cells.

The high level of expression of the $V\beta 6$ family in the synovial and peripheral blood T cells of RA patients, and in the peripheral blood of the control subjects is likely to be related to the size of the $V\beta 6$ family which contains at least nine members. However it is evident from the data in Tables II and III that levels of expression are not strictly dependent on the number of genes in a gene family, and, therefore, are likely to be influenced by thymic selection and antigen stimulation. Within rheumatoid synovium, skewed expression of $V\beta$ gene families among T cells might result from altered migration into and retention in the synovium, or from selective proliferation or activation (or inactivation) of cells utilizing these V gene families.

Superantigen stimulation, characterized by $V\beta$ specific activation of T cells that is often followed by depletion or inactivation of cells bearing the appropriate $V\beta$ (51–54), could account for selective enrichment or depletion of selected $V\beta$ families in RA. Although several superantigens interact with one or more of the relevant $V\beta$ gene families (55), no known superantigen could explain all of the observed biases in the peripheral blood of RA patients who express HLA-DR1 or DR4. Similarly, the current data do not implicate a known superantigen as being responsible for simultaneous expansion of $V\beta 6$ and $V\beta 15$ bearing T cells in rheumatoid synovium. $V\beta 6$ is stimulated by staphylococcal enterotoxin (SE) A (R. Jenkins and D. Karp, unpublished results) and SEE (55), whereas $V\beta 15$ is stimulated by SEB, SEC2 (56), and streptococcal pyrogenic exotoxin (SPE) A (57). However, none of these superantigens interacts with both $V\beta 6$ and $V\beta 15$ bearing T cells. Finally, no known superantigen could explain the observed depletion of several $V\beta$ families in rheumatoid synovium. Nevertheless, it remains possible that the actions of as yet unidentified superantigens account for the biases observed in RA synovium and peripheral blood.

The present study of blood samples from 24 RA patients, 4 control patients, and 15 normal donors, and of synovial tissue from 8 RA patients and 13 RA synovial fluid samples, represents the most extensive examination of $V\beta$ gene utilization in RA to date. The results clearly indicate that the number of $V\beta$ families expressed by RA peripheral blood and synovial T cells is not significantly restricted. More importantly, several lines of evidence indicate biased $V\beta$ gene utilization in different peripheral compartments of rheumatoid patients can be observed in unselected T cell populations. These analyses revealed several statistically significant trends, with either enrichment or depletion of particular $V\beta$ genes noted in the synovium. Increased expression of $V\beta 6$ and $V\beta 15$ was evident in a majority of patients. In addition, $V\beta 4$, $V\beta 5.1$, $V\beta 10$, $V\beta 16$, and $V\beta 19$ expression was decreased in rheumatoid synovium in a majority of the comparisons. Because the PCR assay is sensitive to changes in activation status, alterations in either the number of cells expressing these $V\beta$ families or the activation state of these cells could explain the differences observed in the $V\beta$ -specific PCR products from RA T cells. Therefore, the data are consistent with the postulate that antigen or superantigen driven processes may cause $V\beta$ -specific enrichment or depletion of T cells in RA.

Acknowledgments

This work was supported by grants AR01886-01 and AR39169 from the National Institute of Arthritis, Musculoskeletal and Skin Diseases. Dr. Jenkins is the recipient of an Arthritis Investigator Award from the Arthritis Foundation.

References

1. Cush, J. J., and P. E. Lipsky. 1991. Cellular basis for rheumatoid inflammation. *Clin. Orthopaed. Relat. Res.* 265:9-22.
2. Stastny, P. 1978. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. *N. Engl. J. Med.* 298:869-871.
3. Nepom, G. T., P. Byers, C. Seyfried, L. A. Healey, K. R. Wilske, D. Stage, and B. S. Nepom. 1989. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes. *Arthritis Rheum.* 32:15-21.
4. Schiff, B., Y. Mizrahi, S. Orgad, M. Yaron, and E. Gazit. 1982. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. *Ann. Rheum. Dis.* 41:403-404.
5. Gao, X. J., N. J. Olsen, T. Pincus, and P. Stastny. 1990. HLA-DR alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritis. *Arthritis Rheum.* 33:939-946.
6. Woodrow, J. C., F. E. Nichol, and G. Zaphiropoulos. 1981. DR antigens and rheumatoid arthritis: a study of two populations. *Br. Med. J.* 283:1287-1288.
7. Wordsworth, B. P., J. S. Lanchbury, L. I. Sakkas, K. I. Welsh, G. S. Panayi, and J. I. Bell. 1989. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. *Proc. Natl. Acad. Sci. USA.* 86:10 049-10 053.
8. Gregersen, P. K., J. Silver, and R. J. Winchester. 1987. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 30:1205-1213.
9. Esch, T., L. Clark, X.-M. Zhang, S. Goldman, and E. Heber-Katz. 1992. Observations, legends, and conjectures concerning restricted T-cell receptor usage and autoimmune disease. *Crit. Rev. Immunol.* 11:249-264.
10. Blackman, M., J. Kappler, and P. Marrack. 1990. The role of the T cell receptor in positive and negative selection of developing T cells. *Science (Wash. DC).* 248:1335-1341.
11. Gulwani-Akolkar, B., D. N. Posnett, C. H. Janson, J. Grunewald, H. Wiggzell, P. Akolkar, P. K. Gregersen, and J. Silver. 1991. T cell receptor V-segment frequencies in peripheral blood T cells correlate with human leukocyte antigen type. *J. Exp. Med.* 174:1139-1146.
12. Loveridge, J. A., W. M. Rosenberg, T. B. Kirkwood, and J. I. Bell. 1991. The genetic contribution to human T-cell receptor repertoire. *Immunology.* 74:246-250.
13. Hashimoto, N., and B. J. Goldstein. 1992. Differential regulation of mRNAs encoding three protein-tyrosine phosphatases by insulin and activation of protein kinase C. *Biochem. Biophys. Res. Commun.* 188:1305-1311.
14. Paliard, X., S. G. West, J. A. Lafferty, J. R. Clements, J. W. Kappler, P. Marrack, and B. L. Kotzin. 1991. Evidence for the effects of a superantigen in rheumatoid arthritis. *Science (Wash. DC).* 253:325-329.
15. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. *Science (Wash. DC).* 248:705-711.
16. Savill, C. M., P. J. Delves, D. Kioussis, P. Walker, P. M. Lydyard, B. Colaco, M. Shipley, and I. M. Roitt. 1987. A minority of patients with rheumatoid arthritis show a dominant rearrangement of T-cell receptor beta chain genes in synovial lymphocytes. *Scand. J. Immunol.* 25:629-635.
17. Keystone, E. C., M. Minden, R. Klock, L. Poplonski, J. Zalcberg, T. Takadera, and T. W. Mak. 1988. Structure of T cell antigen receptor beta chain in synovial fluid cells from patients with rheumatoid arthritis. *Arthritis Rheum.* 31:1555-1557.
18. Duby, A. D., A. K. Sinclair, S. L. Osborne-Lawrence, W. Zeldes, L. Kan, and D. A. Fox. 1989. Clonal heterogeneity of synovial fluid T lymphocytes from patients with rheumatoid arthritis. *Proc. Natl. Acad. Sci. USA.* 86:6206-6210.
19. Cush, J. J., A. D. Duby, E. Lightfoot, and P. E. Lipsky. 1991. The search for oligoclonal T cells in rheumatoid synovium. *Arthritis Rheum.* 30:s16. (Abstr.)
20. Stamenkovic, I., M. Stegagno, K. A. Wright, S. M. Krane, E. P. Amento, R. B. Colvin, R. J. Duquesnoy, and J. T. Kurnick. 1988. Clonal dominance among T-lymphocyte infiltrates in arthritis. *Proc. Natl. Acad. Sci. USA.* 85:1179-1183.
21. Cooper, S. M., D. L. Dier, K. D. Roessner, R. C. Budd, and J. A. Nicklas. 1991. Diversity of rheumatoid synovial tissue T cells by T cell receptor analysis: oligoclonal expansion in interleukin-2-responsive cells. *Arthritis Rheum.* 34:537-546.
22. van Laar, J. M., A. M. Miltenburg, M. J. Verdonk, M. R. Daha, R. R. de Vries, P. J. van den Elsen, and F. C. Breedveld. 1992. T-cell receptor beta-chain gene rearrangements of T-cell populations expanded from multiple sites of synovial tissue obtained from a patient with rheumatoid arthritis. *Scand. J. Immunol.* 35:187-194.
23. Chatila, M. K., F. Pandolfi, I. Stamenkovich, and J. T. Kurnick. 1990. Clonal dominance among synovial tissue-infiltrating lymphocytes in arthritis. *Hum. Immunol.* 28:252-257.
24. Sottini, A., L. Imberti, R. Gorla, R. Cattaneo, and D. Primi. 1991. Restricted expression of T cell receptor V beta but not V alpha genes in rheumatoid arthritis. *Eur. J. Immunol.* 21:461-466.
25. Bucht, A., J. R. Oksenberg, S. Lindblad, A. Gronberg, L. Steinman, and L. Klareskog. 1992. Characterization of T-cell receptor alpha beta repertoire in synovial tissue from different temporal phases of rheumatoid arthritis. *Scand. J. Immunol.* 35:159-165.
26. Williams, W. V., Q. Fang, D. Demarco, J. VonFeldt, R. B. Zurier, and D. B. Weiner. 1992. Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. *J. Clin. Invest.* 90:326-333.
27. Krawinkel, U., and G. Pluschke. 1992. T cell receptor variable region repertoire in lymphocytes from rheumatoid arthritis patients. *Immunobiology.* 185:483-491.
28. Lunardi, C., C. Marguerie, and A. K. So. 1992. An altered repertoire of T cell receptor V gene expression by rheumatoid synovial fluid T lymphocytes. *Clin. Exp. Immunol.* 90:440-446.
29. Sioud, M., J. Kjeldsen-Kragh, A. J. Quayle, H. G. Wiker, D. Sorskaar, J. B. Natvig, and O. Forre. 1991. Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatoid patients, and V beta usage by specific synovial T-cell lines and fresh T cells. *Scand. J. Immunol.* 34:803-812.
30. Pluschke, G., G. Ricken, H. Taube, S. Kroninger, I. Melchers, H. H. Peter, K. Eichmann, and U. Krawinkel. 1991. Biased T cell receptor V_α region repertoire in the synovial fluid of rheumatoid arthritis patients. *Eur. J. Immunol.* 21:2749-2754.
31. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 31:315-324.
32. Vartdal, F., G. Gaudernack, S. Funderud, A. Bratlie, T. Lea, J. Ugelstad, and E. Thorsby. 1986. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation—a fast and reliable technique. *Tissue Antigens.* 28:301-312.
33. Gao, X. J., M. Fernandez-Vina, W. Shumway, and P. Stastny. 1990. DNA typing for class II HLA antigens with allele-specific or group-specific amplification. I. Typing for subsets of HLA-DR4. *Hum. Immunol.* 27:40-50.
34. Lanchbury, J. S., M. A. Hall, K. I. Welsh, and G. S. Panayi. 1990. Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing. *Hum. Immunol.* 27:136-144.
35. Kingsley, G. H., C. Pitzalis, and G. S. Panayi. 1987. Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. *J. Rheumatol.* 14:667-673.
36. Erlich, H. A., and T. L. Bugawan. 1989. HLA class II gene polymorphism: DNA typing, evolution and relationship to disease susceptibility. *In* PCR Technology. H. A. Erlich, editor. Stockton, New York. 193-208.
37. Cush, J. J., and P. E. Lipsky. 1988. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. *Arthritis Rheum.* 31:1230-1238.
38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 7.19.
39. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159.
40. Choi, Y. W., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. *Proc. Natl. Acad. Sci. USA.* 86:8941-8945.
41. Karp, D. R., R. N. Jenkins, and E. O. Long. 1992. Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins. *Proc. Natl. Acad. Sci. USA.* 89:9657-9661.
42. Horgan, K. J., G. A. Van-Severter, Y. Shimizu, and S. Shaw. 1990. Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor-mediated stimuli but augmentation of responses by co-stimuli. *Eur. J. Immunol.* 20:1111-1118.
43. Davey, M. P., M. M. Meyer, D. D. Munkirs, D. Babcock, M. P. Braun, J. B. Hayden, and A. C. Bakke. 1991. T-cell receptor variable beta genes show differential expression in CD4 and CD8 T cells. *Hum. Immunol.* 32:194-202.
44. Hawes, G. E., L. Struyk, and P. J. van den Elsen. 1993. Differential usage of T cell receptor V gene segments in CD4+ and CD8+ subsets of T lymphocytes in monozygotic twins. *J. Immunol.* 150:2033-2045.
45. Akolkar, P. N., B. Gulwani-Akolkar, R. Pergolizzi, R. D. Bigler, and J. Silver. 1993. Influence of HLA genes on T cell receptor V segment frequencies and expression levels in peripheral blood lymphocytes. *J. Immunol.* 150:2761-2773.
46. Fox, R. I., S. Fong, N. Sabharwal, S. A. Carstens, P. C. Kung, and J. H.

- Vaughan. 1982. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. *J. Immunol.* 128:351.
47. Reme, T., M. Portier, F. Frayssinoux, B. Combe, P. Miossec, F. Favier, and J. Sany. 1990. T cell receptor expression and activation of synovial lymphocyte subsets in patients with rheumatoid arthritis: phenotyping of multiple synovial sites. *Arthritis Rheum.* 33:485-492.
48. Smith, M. D., and P. J. Roberts-Thomson. 1990. Lymphocyte surface marker expression in rheumatic diseases: evidence for prior activation of lymphocytes in vivo. *Ann. Rheum. Dis.* 49:81-87.
49. Baccala, R., D. H. Kono, S. Walker, R. S. Balderas, and A. N. Theofilopoulos. 1991. Genomically imposed and somatically modified human thymocyte V beta gene repertoires. *Proc. Natl. Acad. Sci. USA.* 88:2908-2912.
50. Cush, J. J., P. Pietschmann, N. Oppenheimer-Marks, and P. E. Lipsky. 1992. The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. *Arthritis Rheum.* 35:1434-1444.
51. Kawabe, Y., and A. Ochi. 1990. Selective anergy of V beta 8+, CD4+ T cells in Staphylococcus enterotoxin B-primed mice. *J. Exp. Med.* 172:1065-1070.
52. Rellahan, B. L., L. A. Jones, A. M. Kruisbeek, A. M. Fry, and L. A. Matis. 1990. In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B. *J. Exp. Med.* 172:1091-1100.
53. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. *Cell.* 63:1249-1256.
54. Kawabe, Y., and A. Ochi. 1991. Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. *Nature (Lond.)*. 349:245-248.
55. Zumla, A. 1992. Superantigens, T Cells, and Microbes. *Clin. Infect. Dis.* 15:313-320.
56. Choi, Y., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of Staphylococcus toxin "superantigens" with human T cells. *Proc. Natl. Acad. Sci. USA.* 86:8941-8945.
57. Tomai, M. A., P. M. Schlievert, and M. Kotb. 1992. Distinct T-cell receptor V beta gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and pep M5 protein. *Infect. Immun.* 60:701-705.
58. Howell, M. D., J. P. Diveley, K. A. Lundeen, A. Esty, S. T. Winters, D. J. Carlo, and S. W. Brostoff. 1991. Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. *Proc. Natl. Acad. Sci. USA.* 88:10 921-10 925.